In addition, the largest studies conducted recently have compared infection risk among RRMS patients with rituximab, natalizumab, fingolimod, interferon beta, and glatiramer acetate (19), showing that rituximab was associated with the highest rate of serious infections, while other DMDs increased the risk of infection-related physician claims, but not hospitalization, indicating that DMDs may cause minor infections, but not severe infection requiring hospitalization. Here, IFNB1 is linked to infection.